Repligen (NASDAQ:RGEN – Get Free Report) released its earnings results on Wednesday. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33, Briefing.com reports. The business had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. Repligen had a return on equity […]
Repligen (NASDAQ:RGEN – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $1.42-1.49 for the period, compared to the consensus estimate of $1.77. The company issued revenue guidance of $620-650 million, compared to the consensus revenue estimate of $660.67 million. Repligen also […]
Repligen (NASDAQ:RGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.770. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $660.7 million. Repligen […]
Repligen (NASDAQ:RGEN – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.770. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $660.7 million. Repligen also updated […]
Repligen (NASDAQ:RGEN – Free Report) had its target price lifted by KeyCorp from $210.00 to $220.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. RGEN has been the subject of several other research reports. JPMorgan Chase & Co. upped their price target on […]